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Human embryonic stem cells (hESC) and induced pluripotent stem cells (hiPSC) are an
attractive cell source for regenerative medicine. These cells can be expanded to vast
numbers and can be differentiated to many desired pluripotent stem cells (PSC) derived
therapeutic cells. Cell replacement bears promises, but also challenges.The introduction of
exogenous cells in a recipientmust address several different topics; its safety, the exclusion
of tumor formation, the immunological response and possible rejection, the cells cleanli-
ness and their biological quality, and quantity representing the functionality of the PSC
derived therapeutic cells.Tumor formation requires the removal of any PSC remaining after
differentiation. Immunological rejection can be addressed with immunomodulation of the
cells and the recipient. Cleanliness can be optimized using good manufacturing practice
quality systems. At last, the functionality of the cells must be tested in in vitro and in animal
models. After addressing these challenges, precise strategies are developed to monitor
the status of the cells at different times and in case of undesired results, corresponding
counteracting strategies must exist before any clinical attempt.
Keywords: cell transplantation,humanembryonic stemcells, humanpluripotent stemcells,GMP, immunoreactivity,
tumorigenic
CULTURE CONDITIONS OF PLURIPOTENT CELLS
After initial establishment and derivation of human embryonic
stem cells (hESC; Thomson et al., 1998; Reubinoff et al., 2000)
their potential therapeutic use in cell replacement strategies was
clear. Before cell transplantation, several steps must be fulﬁlled.
First the infection free status of the donors has to be addressed, In
Europe couples are tested before any fertility treatment is offered,
but the cells themselves have to be tested, too (Hovatta, 2011). Sec-
ond, optimized good manufacturing practice (GMP) compliant
systems must be implemented for derivation, scaling-up, bank-
ing of cells, and their corresponding quality assurance controls
(Unger et al., 2008; Ausubel et al., 2011). The culture systems
currently encounter the problem of suboptimal quality of xeno-
free culture constituents. Thus strategies are needed to overcome
this difﬁculty (Sidhu et al., 2008). Steps have been taken; initially,
hESC were grown on irradiated mouse feeders, later human fore-
skin ﬁbroblast were used (Hovatta et al., 2003), now we can use
GMP compliant coating substrates specially designed for hESC
growth (Rodin et al., 2010). Steps were also taken for the gen-
eration deﬁned xeno-free GMP compliant medium for derivation
and for expansion (Ludwig et al., 2006; Rajala et al., 2010; Ilic et al.,
2012).
REPROGRAMMING AND hiPSC
The potential of somatic cell reprogramming via expression of
speciﬁc transcription factors and thus the generation of hESC
induced pluripotent stem cells (hiPSC; Takahashi and Yamanaka,
2006; Takahashi et al., 2007) has the advantage that they could
be generated from the recipient patients own cells. This could
overcome an allogenic immune rejection (Li and Zhong, 2009).
But this potential although tempting, has not been proven. There
is no deep understanding of the effects that the reprogramming
events have; for instance on extracellular signaling (Okita et al.,
2011), and the way that this could lead to immune reaction. It was
shown that speciﬁc T cells were reactive toward Oct-4 antigens.
Hence fast reactivity is already present in healthy individuals for
controlling any rapidly amplifying cells (Dhodapkar et al., 2010).
Un-silenced expression of the reprogramming factor Oct-4 might
then cause undesired immunoreactivity on the transplanted cells.
Immunoreactivity toward graft-derived hiPSC of the same genetic
background was also shown in animal models (Zhao et al., 2011).
For successful reprogrammingof somatic cells,many epigenetic
changes must occur in an adequate manner. Failure will result in
abnormal phenotypes (Mikkelsen et al., 2008). DNA methylation
changes during reprogramming must occur in important devel-
opmental and oncogenic regions, which increases the oncogenic
risk of the reprogrammed cells (Doi et al., 2009; Ohm et al., 2010).
There is an additional risk for abnormalities and high tumorigenic
potential, especially if c-myc is used as one of the transcription
factors (Okita et al., 2007). Also, genetic and epigenetic stabil-
ity and large-scale genomic rearrangements after reprogramming
and subsequent culture (Kim et al., 2010; Gore et al., 2011;Hussein
et al., 2011; Lister et al., 2011) might challenge the application of
hiPSC under a clinical cell replacement therapy. Further studies
to clarify these issues are needed (Pera, 2011). It is also important
to address the safety of long-term culture, as shown recently; the
occurrence of chromosomal rearrangements in long-term culture
of 125 hESC and 11 hiPSC (Amps et al., 2011).
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PLURIPOTENT STEM CELL DIFFERENTIATION
There is a consensus that undifferentiated pluripotent stem cells
(PSC)will not be used directly in any clinical transplantations pro-
cedure, but instead their PSC derived differentiated cells Recently,
results using hESC derived dopaminergic neurons have shown
correct phenotype differentiation and grafting potential given by
no tumor formation, maintenance of the grafted cells, and func-
tional recovery in parkinsonian animal models in mice, rats, and
monkeys (Kriks et al., 2011). The protocols designed for this cell
replacement assay were optimal regarding the phenotype, quantity
of the cells, functionality, and immunological properties. Inte-
gration of transplanted cells was achieved when single cells were
transplanted, the use of proper biodegradable scaffolds must also
be considered. In addition to this initial report regarding the neural
lineage, differentiation protocols for other cell types are needed.
Even if transplantation in animal models is successful, it
is important to generate safety strategies before clinical trials
to appropriately remove undifferentiated PSC from their PSC
derived therapeutic cells. Strategies such as inserting suicide gene
(Drobyski et al., 2003; Uchibori et al., 2009) might have contro-
versial outcomes under clinical trials given their safety (Yi et al.,
2011). Alternatively, strategies such as removal of undifferentiated
cells using antibodies might be safer (Tang et al., 2011).
THE IMMUNOGENIC PROFILES
As discussed earlier, an optimal engraftment and cell replacement
strategy should account for a minimal immune reaction in the
recipient. This immune reaction occurs because the immune sys-
tem of the recipient recognizes the grafted cells as foreign material
or mismatched cellular components and thus generates a cas-
cade of events that ultimately results in destruction and rejection
of the grafted cells. This destruction can also compromise the
recipient’s immune status (Petersen et al., 1975). Immunoreac-
tivity toward the graft is mainly caused by T cell response toward
unmatchedmajor histocompatibility complex (MHC); in humans
calledhuman leukocyte antigen (HLA). If theproﬁle is unmatched,
it will result in rejection (Lechler et al., 2005). This rejection can
occur via direct allorecognition of the donor antigen presenting
cells (APC) or via indirect recognition of apoptotic cells ingested
by the recipients APC, in both cases APCs presenting unmatched
MHCs (Walsh et al., 2004). Several groups have studiedMHCpro-
ﬁles of hESCand their differentiated cells (Swijnenburg et al., 2008;
Pearl et al., 2011). Findings are that undifferentiated cells express
MHC I antigens, though at low levels compared with somatic
cells; but they do not express MHC II molecules (Drukker et al.,
2002, 2006; Li et al., 2004). During in vitro differentiation toward
germ lineages, embryoid body (EB) formation, or teratoma for-
mation MHC I expression increases dramatically (Drukker and
Benvenisty, 2004). Also culture methods of hESC can change anti-
gen expression levels (Rajala et al., 2010). Careful selection of
culture conditions, both for the undifferentiated hESC and for
their differentiated derivatives is needed.
Human embryonic stem cells adopts the expression of non-
human cell surface markers if exposed to such substances during
culture (Martin et al., 2005; Hisamatsu-Sakamoto et al., 2008).
Hence, optimal culture conditions must be xeno-free from the
initial derivation and onward. These culture conditions must be
carefully analyzed and scientiﬁc consensus must be achieved in
order to raise current methodologies.
IMMUNOSUPPRESSION
Challenges with the immunoreactivity of the transplantable cells
could be addressed by rigorous immunosuppressive treatments.
Unfortunately, this is not desired, since there is a clear correla-
tion between the length and intensity of exposure to immuno-
suppressive therapy and post-transplant risk of malignancy and
tumor aggressiveness (Gutierrez-Dalmau and Campistol, 2007).
An interesting solution is costimulatory blockage of T cell response
(Grinnemo et al., 2006, 2008; Swijnenburg et al., 2008; Pearl
et al., 2011). This immunosuppression strategy will generate tol-
erance to the grafted cells and thus increase graft survival; initial
pharmaceutical agents have been developed and pending clini-
cal applications to the FDA are to give in the near future more
information.
DISCUSSION
In this mini-review we highlighted the most important areas to
be considered under a cell replacement therapy. The possibility of
using hiPSC derived therapeutic cells in cell replacement thera-
pies requires still long-term studies in non-human animal mod-
els addressing the questions of immunogenicity, epigenetic and
genetic stability of these cells, and the optimized differentiation of
the cells.
The importance of proﬁling immunogenic markers as part of
the stem-ness characterization and proﬁling of cells allocated in
stem cell banksmust be consider. The allocation and custody of the
characterization data is equally important. Such information has
to be well protected so that it will not be lost in any given situation.
Adequate culture conditions, supporting correct immunogenicity
of the cells under a transplantation assay is also required.
Next, the management of immunosuppression schemes must
aim to a minimal time inﬂuencing the immunological status of
the recipient.
From all the information obtained, proﬁles can be generated
before and after differentiation. These proﬁles can then be used in
combination with methodologies focused at monitoring the sta-
tus of the transplanted cells. In a given scenario that undesired
cells persist in the transplant, adequate counteracting actions have
immediately to be taken. Such possibilities have to be tested and
the removal of undesired effects conﬁrmed before starting cell
transplantations. Failure in any particular cell replacement clin-
ical trial will imply disastrous effects. Responsible decisions are
needed under complete scrutiny from medical agencies and the
scientiﬁc community.
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